ClinicalTrials.gg

Program

ompekimig

Also written as “PF-07264660”, “PF-07264660 intravenous single ascending dose” and “PF-07264660 subcutaneous multiple ascending dose”.

In Pfizer's pipeline, anti-IL-4/ IL-13/ IL-33. Its studies are mostly in Dermatitis, Atopic, led by Pfizer.

Furthest: phase 2, since Jul 26, 20233 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer31 open or runningphase 2since Jul 26, 2023Aug 9, 2022none ahead
  • Named in Pfizer’s own pipeline as ompekimig, phase 2, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 9, 2022First study: phase 1 study in HealthyFirst studyNCT05496738 · 59 enrolled · United States
  2. Jul 26, 2023Phase 2 study in Dermatitis, AtopicNCT05995964 · 507 enrolled · United States, Australia, Canada and more
  3. Nov 26, 2024Phase 1 study in HealthyNCT06712082 · 12 enrolled · China

Ahead

  1. Nov 12, 2026Primary completion: phase 2 study in Dermatitis, AtopicNCT05995964

TargetBeta

“anti-IL-4/ IL-13/ IL-33”the company's pipeline, read by Claude · source

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06712082Healthy · China1CompletedSep 4, 202512
NCT05995964Dermatitis, Atopic · United States, Australia, Canada and more2Active, not recruitingNov 12, 2026507
NCT05496738Healthy · United States1CompletedMay 6, 202459

How it is read

Names in the registry

  • “PF-07264660”, 2 entries
  • “PF-07264660 intravenous single ascending dose”, 1 entry
  • “PF-07264660 subcutaneous multiple ascending dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.